Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program
Phase 3negativeVQW-765Negative
AI Analysis
Summary
Vanda Pharmaceuticals announced that VQW-765 failed to meet its primary endpoint in a Phase III clinical study for social anxiety disorder, though the drug was confirmed to be safe and well tolerated. The negative Phase 3 result represents a significant setback for the program.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Not Met
Outcome Details
Phase III clinical study did not meet its primary endpoint
Importance:8/10
Sentiment:
-0.70
Phase 3 failureclinical trialsocial anxiety disordersafety profile maintained
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 14, 2026 9:00 PM